Abstract:Objective: The mutant γ-aminobutyric acid type A (GABAA ) receptor γ2(Q390X) subunit (Q351X in the mature peptide) has been associated with the epileptic encephalopathy, Dravet syndrome, and the epilepsy syndrome genetic epilepsy with febrile seizures plus (GEFS+). The mutation generates a premature stop codon that results in translation of a stable truncated and misfolded γ2 subunit that accumulates in neurons, forms intracellular aggregates, disrupts incorporation of γ2 subunits into GABAA receptors, and affects trafficking of partnering α and β subunits. Heterozygous Gabrg2+/Q390X knock-in (KI) mice had reduced cortical inhibition, spike wave discharges on electroencephalography (EEG), a lower seizure threshold to the convulsant drug pentylenetetrazol (PTZ), and spontaneous generalized tonic-clonic seizures. In this proof-of-principal study, we attempted to rescue these deficits in KI mice using a γ2 subunit gene (GABRG2) replacement therapy. Methods: We introduced the GABRG2 allele by crossing Gabrg2+/Q390X KI mice with bacterial artificial chromosome (BAC) transgenic mice overexpressing HA (hemagglutinin)-tagged human γ2HA subunits, and compared GABAA receptor subunit expression by Western blot and immunohistochemical staining, seizure threshold by monitoring mouse behavior after PTZ-injection, and thalamocortical inhibition and network oscillation by slice recording. Results: Compared to KI mice, adult mice carrying both mutant allele and transgene had increased wild-type γ2 and partnering α1 and β2/3 subunits, increased miniature inhibitory postsynaptic current (mIPSC) amplitudes recorded from layer VI cortical neurons, reduced thalamocortical network oscillations, and higher PTZ seizure threshold. Significance: Based on these results we suggest that seizures in a genetic epilepsy syndrome caused by epilepsy mutant γ2(Q390X) subunits with dominant negative effects could be rescued potentially by overexpression of wild-type γ2 subunits.

Prime editing-based gene correction alleviates the hyperexcitable phenotype and seizures of a genetic epilepsy mouse model

Rapid modeling of an ultra-rare epilepsy patient variant in mice by in utero prime editing

Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases

Targeted Reducing of Tauopathy Alleviates Epileptic Seizures and Spatial Memory Impairment in an Optogenetically Inducible Mouse Model of Epilepsy

Modeling a Cataract Disorder in Mice with Prime Editing.

Improved Prime Editors Enable Pathogenic Allele Correction and Cancer Modelling in Adult Mice

Allele‐Specific Editing of a Dominant SCN8A Epilepsy Variant Protects against Seizures and Lethality in a Murine Model

Decreased Synapse‐associated Proteins Are Associated with the Onset of Epileptic Memory Impairment in Endothelial CDK5‐deficient Mice

Amelioration of Metabolic and Behavioral Defects Through Base Editing in the PahR408W Phenylketonuria Mouse Model

In Vivo Base Editing of Scn5a Rescues Type 3 Long QT Syndrome in Mice

Whole-brain in vivo base editing reverses behavioral changes in Mef2c-mutant mice

Functional characterization of a KCNAB3 genetic epilepsy with febrile seizures plus adult mouse model

Treatment of a genetic liver disease in mice through transient prime editor expression

Correction of Beta-Thalassemia IVS-II-654 Mutation in a Mouse Model Using Prime Editing

CRISPR/Cas9-mediated Gene Editing Ameliorates Neurotoxicity in Mouse Model of Huntington’s Disease

CRISPR-Cas9–mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis

Overexpressing wild-type γ2 subunits rescued the seizure phenotype in Gabrg2+/Q390X Dravet syndrome mice

Whole-brain in vivo base editing reverses autistic-like behaviors in mice

Epilepsy phenotype and response to KCNQ openers in mice harboring the Kcnq2 R207W voltage-sensor mutation

Mutation of the murine Prickle1 (R104Q) causes phenotypes analogous to human symptoms of epilepsy and autism

METTL14/YTHDC1-Mediated m6A Modification in Hippocampus Improves Pentylenetetrazol-Induced Acute Seizures